Orlando, 26 June 2010: Linagliptin, a dipeptidyl dipeptidase (DPP)-4 inhibitor being developed by Boehringer Ingelheim, achieves significant reductions in blood glucose in patients with type 2 diabetes both as monotherapy and in combination with other commonly used hypoglycaemic agents, according to four phase III trials reported at the American Diabetes Association meeting (25-29 June 2010, Orlando, Florida)...![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2Fi2A5C4rXSKYLrrqzSblw9K2nUmI%2F0%2Fdi&hash=575811f61573a5c644815bdbc3be38a5)
![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2Fi2A5C4rXSKYLrrqzSblw9K2nUmI%2F1%2Fdi&hash=2d13bf67d3681e81c097d78d6dd4801f)
More...
More...